已有研究表明，GRIK1 可抑制 NLRP3 炎性小体（NLRP3 inflammasome）的激活。本研究聚焦炎性小体，探究 GRIK1 对最常见的神经退行性疾病 —— 阿尔茨海默病（Alzheimer’s disease，AD）的损伤作用。研究人员对 APP-PS1 小鼠进行 Y 迷宫测试和莫里斯水迷宫测试，并利用腺相关 ...

其中，NLRP3 炎性小体（Nucleotide-binding oligomerization domain 、leucine-rich repeat 、pyrin domain–containing protein 3 inflammasome）在炎症反应中扮演着极为重要的角色，它就像免疫系统里的一个 “开关”，一旦被异常激活，会导致多种炎症性、自身免疫性和退行性疾病的发生。

Scientists from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented NLRP3 inflammasome and interleukin-1β (IL1B; IL-1β) release inhibitors reported to be useful for the treatment of ...

Now, a groundbreaking study from the University of California, Berkeley has identified a molecular switch that may help control chronic inflammation. This discovery could lead to new treatments that ...

ZyVersa Therapeutics (ZVSA) highlights newly published animal model data demonstrating that inflammasome inhibition attenuates ...

The activation of the NLRP3 inflammasome is a key factor driving kidney inflammation, but it remains unclear whether CRP enhances inflammation in DKD through the NLRP3 inflammasome pathway.

Then, in 2001, researchers in California discovered the genetic explanation for his disease: a mutation in a gene called CIAS1 (since renamed NALP3 and then NLRP3), which was later found to cause the ...

The research team led by Professor Chen Haiyong (middle) discovers a mechanism of C-reactive protein that exacerbates inflammation in diabetic kidney ...

Therapeutic inhibition of NLRP3 can prevent the formation of the NLRP3 inflammasome, which in turn inhibits the production of IL-1β and IL-18 as well as pyroptosis. Aberrant activation of the ...